Nexalin Technology (NXL) FCF Margin Growth (1y) (2022 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -80.00 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 473.00 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 23.00 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -431.00 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -1,716.00 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 2,811.00 |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 2,833.00 |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 192.00 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 261.00 |
| 10 | Nexalin Technology | 11.19 Mn | 8.48 Mn | 13,133.00 | -831,042.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -831,042.00 |
| Dec 31, 2025 | 350,623.00 |
| Sep 30, 2025 | -585,810.00 |
| Jun 30, 2025 | 334,455.00 |
| Mar 31, 2025 | -250,707.00 |
| Dec 31, 2024 | 71,503.00 |
| Sep 30, 2024 | 68,664.00 |
| Jun 30, 2024 | -234,896.00 |
| Mar 31, 2024 | 333,163.00 |
| Dec 31, 2023 | -253,003.00 |
| Sep 30, 2023 | -273,448.00 |
| Jun 30, 2023 | -225,574.00 |
| Mar 31, 2023 | -423,899.00 |
| Dec 31, 2022 | -65,447.00 |